KBP Biosciences, which is developing drugs for disease areas of unmet need, raised the series A funds from investors including Cash Capital.
US-based biopharmaceutical developer KBP Biosciences closed a $76m series A round backed by Cash Capital, the investment arm of Chinese Academy of Sciences, on Friday.
The round was co-led by venture capital firm Advantech Capital and Chinese government-owned investment firm State Development & Investment Corporation, which invested through its SDIC Venture Capital unit.
Ping An Ventures, a corporate venturing subsidiary of insurance group Ping An, also participated, as did Sangel Capital Management, Bay City Capital GF Xinde Life Science Investment…